Патогенез, ангиогенез диабетического макулярного отека и общая характеристика его лечения (Обзор литературы. Часть I)

    1. Sun H, Saeedi P, Karuranga S, Pinkepank M, et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res. Clin. Pract. 2022;183: 109119. doi: 10.1016/j.diabres.2021.109119

    2. Im JHB, Jin YP, Chow R, Yan P. Prevalence of diabetic macular edema based on optical coherence tomography in people with diabetes: A systematic review and meta-analysis. Surv Ophthalmol. 2022; 67(4): 1244–1251. doi: 10.1016/j.survophthal.2022.01.009

    3. Murakami T, Ishihara K, Terada N, et al. Pathological Neurovascular Unit Mapping onto Multimodal Imaging in Diabetic Macular Edema. Medicina (Kaunas). 2023;59(5): 896. doi: 10.3390/ medicina59050896

    4. Tatsumi T. Current Treatments for Diabetic Macular Edema. Int J Mol Sci. 2023;24(11): 9591. doi: 10.3390/ijms24119591

    5. Lai D, Wu Y, Shao C, Qiu Q. The Role of Muller Cells in Diabetic Macular Edema. Invest Ophthalmol Vis Sci. 2023;64(10): 8. doi: 10.1167/iovs.64.10.8

    6. Hui VWK, Szeto SK, Tang F, et al. Optical coherence tomography classification systems for diabetic macular edema and their associations with visual outcome and treatment responses-an updated review. Asia Pac J Ophthalmol. 2022;11: 247–257. doi: 10.1097/APO.0000000000000468

    7. Choi MY, Jee D, Kwon JW. Characteristics of diabetic macular edema patients refractory to anti-VEGF treatments and a dexamethasone implant. PLoS One. 2019;14(9): e0222364. doi: 10.1371/journal.pone.0222364

    8. Miller K, Fortun JA. Diabetic Macular Edema: Current Understanding, Pharmacologic Treatment Options, and Developing Therapies. Asia-Pac. J Ophthalmol. 2018;7: 28–35. doi: 10.22608/APO.2017529

    9. Campochiaro PA, Akhlaq A. Sustained suppression of VEGF for treatment of retinal/choroidal vascular diseases. Prog Retin Eye Res. 2021;83: 100921. doi: 10.1016/j.preteyeres.2020.100921

    10. Carpi-Santos R, de Melo Reis RA, Gomes FC, Calaza KC. Contribution of Muller cells in the diabetic retinopathy development: focus on oxidative stress and inflammation. Antioxidants. 2022;11: 614. doi: 10.3390/antiox11040617

    11. Pozarowska D, Pozarowski P. The era of anti-vascular endothelial growth factor (VEGF) drugs in ophthalmology, VEGF and antiVEGF therapy. Cent Eur J Immunol. 2016;41(3): 311–316. doi: 10.5114/ceji.2016.63132

    12. Furino C, Boscia F, Reibaldi M, Alessio G. Intravitreal Therapy for Diabetic Macular Edema: An Update. J Ophthalmol. 2021;2021: 6654168. doi: 10.1155/2021/6654168

    13. Wu J, Zhong Y, Yue S, et al. Aqueous Humor Mediator and Cytokine Aberrations in Diabetic Retinopathy and Diabetic Macular Edema: A Systematic Review and Meta-Analysis. Dis Markers. 2019;2019: 6928524. doi: 10.1155/2019/6928524

    14. Курышева Н.И., Сергушев С.Г., Наумова В.И., Иванова А.А. Эволюция применения ингибиторов ангиогенеза в офтальмологии. Эффективная фармакотерапия. 2022;18(11): 58–67. [Kurysheva NI, Sergushev SG, Naumova VI, Ivanova AA. Evolution of the Use of Angiogenesis Inhibitors in Ophthalmology. Effective pharmacotherapy. 2022;18 (11): 58–67. (In Russ.)] doi: 10.33978/2307-3586-2022-18-11-58-67

    15. Glassman AR, Wells JA 3rd, Josic K, et al. Five-Year Outcomes after Initial Aflibercept, Bevacizumab, or Ranibizumab Treatment for Diabetic Macular Edema (Protocol T Extension Study). Ophthalmology. 2020;127(9): 1201–1210. doi: 10.1016/j.ophtha.2020.03.021

    16. Sivaprasad S, Oyetunde S. Impact of injection therapy on retinal patients with diabetic macular edema or retinal vein occlusion. Clin Ophthalmol. 2016;10: 939–946. doi: 10.2147/OPTH.S100168

    17. Egan C, Zhu H, Lee A, et al. The United Kingdom Diabetic Retinopathy Electronic Medical Record Users Group, Report 1: baseline characteristics and visual acuity outcomes in eyes treated with intravitreal injections of ranibizumab for diabetic macular oedema. Br J Ophthalmol. 2017;101(1): 75–80. doi: 10.1136/ bjophthalmol-2016-309313

    18. Blinder KJ, Dugel PU, Chen S, et al. Anti-VEGF treatment of diabetic macular edema in clinical practice: effectiveness and patterns of use (ECHO Study Report 1). Clin Ophthalmol. 2017;11: 393–401. doi: 10.2147/OPTH.S128509

    19. Weiss M, Sim DA, Herold T, et al. Compliance and adherence of patients with diabetic macular edema to intravitreal anti-vascular endothelial growth factor therapy in daily practice. Retina. 2018;38(12): 2293–2300. doi: 10.1097/IAE.0000000000001892